NEW YORK – A group of researchers at Memorial Sloan Kettering Cancer Center (MSK) and Epic Sciences has identified a chromosomal instability biomarker in circulating tumor cells (CTCs) that it believes can potentially help guide treatment for metastatic castration-resistant prostate cancer (mCRPC).
San Diego-based Epic Sciences may also pursue the development of a multi-marker panel integrating the new biomarker along with others for predicting prostate cancer treatment response, depending on the results of future validation studies.